Combined BRAF, EGFR, and MEK Inhibition in Patients with &ITBRAF&ITV600E-Mutant Colorectal Cancer
Top Cited Papers
Open Access
- 31 March 2018
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 8 (4), 428-443
- https://doi.org/10.1158/2159-8290.CD-17-1226
Abstract
Although BRAF inhibitor monotherapy yields response rates > 50% in BRAF(V600)-mutant melanoma, only approximately 5% of patients with BRAF(V600E) colorectal cancer respond. Preclinical studies suggest that the lack of efficacy in BRAF(V600E) colorectal cancer is due to adaptive feedback reactivation of MAPK signaling, often mediated by EGFR. This clinical trial evaluated BRAF and EGFR inhibition with dabrafenib (D) + panitumumab (P) +/- MEK inhibition with trametinib (T) to achieve greater MAPK suppression and improved efficacy in 142 patients with BRAF(V600E) colorectal cancer. Confirmed response rates for D+P, D+T+P, and T+P were 10%, 21%, and 0%, respectively. Pharmacodynamic analysis of paired pretreatment and on-treatment biopsies found that efficacy of D+T+P correlated with increased MAPK suppression. Serial cell-free DNA analysis revealed additional correlates of response and emergence of KRAS and NRAS mutations on disease progression. Thus, targeting adaptive feedback pathways in BRAF(V600E) colorectal cancer can improve efficacy, but MAPK reactivation remains an important primary and acquired resistance mechanism. SIGNIFICANCE: This trial demonstrates that combined BRAF + EGFR +MEK inhibition is tolerable, with promising activity in patients with BRAF(V600E) colorectal cancer. Our findings highlight the MAPK pathway as a critical target in BRAF(V600E) colorectal cancer and the need to optimize strategies inhibiting this pathway to overcome both primary and acquired resistance. (C) 2018 AACR.Keywords
Other Versions
Funding Information
- Damon Runyon Cancer Research Foundation (Damon Runyon) (Clinical Investigator Award)
- HHS | NIH | National Cancer Institute (NCI) (P50CA127003)
- HHS | NIH | National Cancer Institute (NCI) (R01CA208437)
- American Association for Cancer Research (AACR) (SU2C-AACR-DT22-17)
This publication has 48 references indexed in Scilit:
- Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer PrognosticationJNCI Journal of the National Cancer Institute, 2013
- The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-AnalysisPLOS ONE, 2012
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with VemurafenibCancer Discovery, 2012
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibNew England Journal of Medicine, 2012
- BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E MutationScience Signaling, 2010
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFNature, 2010
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAFCell, 2010
- CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancerNature Genetics, 2006
- Mutations of the BRAF gene in human cancerNature, 2002